<- Go Home
Checkmate Pharmaceuticals, Inc.
Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; in combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. The company was incorporated in 2015 and is based in Cambridge, Massachusetts. Checkmate Pharmaceuticals, Inc. operates as a subsidiary of Regeneron Pharmaceuticals, Inc.
Market Cap
$231.3M
Volume
38.0K
Cash and Equivalents
$39.5M
EBITDA
N/A
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$10.50
52 Week Low
$2.00
Dividend
N/A
Price / Book Value
4.13
Price / Earnings
-3.60
Price / Tangible Book Value
4.13
Enterprise Value
$171.3M
Enterprise Value / EBITDA
N/A
Operating Income
-$63.2M
Return on Equity
75.44%
Return on Assets
-42.31
Cash and Short Term Investments
$60.0M
Debt
N/A
Equity
$55.0M
Revenue
N/A
Unlevered FCF
-$23.7M
Sector
Biotechnology
Category
N/A